pushes to loosen restrictions on a handful of trendy peptide therapies, scientists who work under him are recommending the opposite
One regulatory note worth holding alongside his framing: the FDA placed several of the peptides he discusses (including BPC-157, CJC-1295, and Ipamorelin) onto a Category 2 list in 2023, citing a lack of safety data rather than reported harms
Thats why weve distinguished collagen peptides as the easiest-to-use muscle growth peptide: theyre usually administered via tablet, capsule, or powdered drink mix, whereas our other recommendations are almost always injected
Meticulous lab work
S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D., Vrcic, H., & Sebecic, B
2021 Nov;39(11):2409-18